While our meta-analysis provides valuable insights into the efficacy and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma (HCC), there are several limitations to consider. Here, CD274 is linked to hepatocellular carcinoma.